Multiple

Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia

Data presented at the 11th International Myeloma Workshop held inKos, Greece demonstrates clinical activity of perifosine incombination with bortezomib, dexamethasone and lenalidomide plusdexamethasone, in patients with relapsed/refractory multiplemyeloma, and as a single agent in patients with relapsed/refractoryWaldenstrom's macroglobulinemia NEW YORK, June 29, 2007 /PRNewswire-FirstCal...

Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma

- 100 percent of patients treated with VELCADE, cyclophosphamide,and prednisone alive at one year - KOS, Greece, June 28, 2007 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. today reported on the presentation of resultsfrom clinical trials of VELCADE based therapies that showed highcomplete remission / complete response(1) (CR) rates in previouslytreated multiple myeloma (MM) p...

Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients

-- 100 percent response rate achieved with VELCADE, lenalidomideand dexamethasone KOS, Greece, June 28 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. (Nasdaq: MLNM) today reported on thepresentation of results from four clinical trials of VELCADE basedtherapies that showed consistently high survival and completeremission / complete response(1) (CR) rates in newly diag...

Gentium's Defibrotide Seen as Active in Multiple Myeloma

NEW YORK--(BUSINESS WIRE)--Jun 27, 2007 - Gentium S.p.A. (Nasdaq:GENT) announced the presentation of both clinical and preclinicaldata that support the safety, activity, synergy and potentialmechanism of action of Defibrotide in combination with anticancertherapy in multiple myeloma. Investigators presented both an updatefrom the Company's ongoing Phase I/II clinical trial for patientswith...

ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model

KOS, Greece--(BUSINESS WIRE)--Jun 26, 2007 - Acceleron Pharma,Inc., a biopharmaceutical company developing therapeutics for thetreatment of musculoskeletal, metabolic and cancer-relateddiseases, today announced results demonstrating that ACE-011, anovel anabolic bone agent for the treatment of bone loss, preservedbone mass and architecture in a murine model of multiple myeloma.Multiple myel...

New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes

* Significant blood sugar reductions seen across range ofpatient populations, including varied ethnic groups, the elderly,and those at high risk of developing diabetes * Galvus lowers blood sugar when added to a sulfonylurea,reinforcing efficacy in combination with commonly used diabetesmedicines * Data confirm good tolerability in humans with studies showingincidence of sid...

CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS

LOS ANGELES--(BUSINESS WIRE)--Jun 25, 2007 - CytRx Corporation(NASDAQ:CYTR), a biopharmaceutical company engaged in thedevelopment and commercialization of human therapeutics, todayreported safety and tolerability results from its previouslyannounced double-blind, placebo-controlled, rising multiple doseclinical trial in healthy volunteers with its drug candidatearimoclomol. CytRx believes...

Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 21, 2007 - OpexaTherapeutics, Inc. (NASDAQ:OPXA), a company involved in thedevelopment and commercialization of cell therapies, todayannounced positive top-line data in an open-label Phase I/IIextension clinical trial of the investigational T-cell vaccine,Tovaxin(TM), for multiple sclerosis (MS). In this one-year,8-subject extension clinical trial...

Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop

-- More than 70 abstracts highlight VELCADE efficacy in broad rangeof patients and across continuum of care -- CAMBRIDGE, Mass., June 19, 2007 /PRNewswire-FirstCall/ --Millennium Pharmaceuticals, Inc. today announced that data forVELCADE, the market leading therapy with unsurpassed single-agentefficacy for patients with previously treated multiple myeloma(MM), will be featured at the upco...

New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines

Study Results Published in Cancer Research TARRYTOWN, N.Y., June 15, 2007 /PRNewswire-FirstCall/ -- EpiCeptCorporation today announced the results of scientific studies that(1) demonstrate that Azixa(TM) (MPC-6827) is effective in treatingmultiple types of human tumors in animal models, (2) reveal amechanism by which MPC-6827 exerts its effects, and (3) show thatMPC-6827 is not affected b...

Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis

- New Data from Open-Label Study Presented at Federation ofClinical Immunology Societies (FOCIS) Annual Meeting - CARLSBAD, Calif., June 11, 2007 /PRNewswire-FirstCall/ --Orchestra Therapeutics, Inc. (Bulletin Board: OCHT) announced todaypositive new data from its completed Phase II open-label study ofNeuroVax(TM), an investigational T Cell Receptor (TCR) peptidevaccine for the treatment...

Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks

Nearly Twice as Many Patients Taking Trexima were Migraine FreeCompared to Placebo CHICAGO, June 08, 2007 /PRNewswire/ -- New data from two largetrials show that Trexima, when taken early, was nearly twice aseffective as placebo in eliminating all traditional migrainesymptoms at two and four hours across multiple attacks with justone tablet. The findings will be presented tomorrow at the...

Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma

Data Presented at the ASCO Cancer Conference NORTH HOLLYWOOD, Calif., and CHICAGO, June 04, 2007 /PRNewswire/-- The International Myeloma Foundation (IMF)-supporting researchand providing education, advocacy and support for myeloma patients,families, researchers and physicians-today said that data from afollow-up to a Phase 3 multi- national clinical trial shows thecombination of DOXIL(R)...

New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma

- Positive data on subcutaneous administration show potential fornew option to improve convenience for patients - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. today announced the presentation of positivedata for VELCADE, the market-leading therapy for patients withmultiple myeloma (MM) who have received at least one prior therapy.These data include resu...

Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75

Phase III Clinical Data on Thalidomide in Multiple MyelomaPresented at the American Society of Clinical Oncology 43rd AnnualMeeting CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- PharmionCorporation today reported the final results of a Phase III studydemonstrating that the addition of Thalidomide to standard therapyimproves overall survival (OS) by 17.6 months in patients aged 75or ol...

Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO

Tanespimycin TIME Registration Program to Begin Third Quarter 2007 HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented data from a dose-escalatingPhase 1b clinical trial of its lead Hsp90 inhibitor, tanespimycin(KOS-953) in combination with bortezomib (Velcade(R)), showing ahigh degree of antitumor activity and tolerability in patients withmult...

Annual Meeting of the Consortium of Multiple Sclerosis Centers Focuses on the Challenges of Care and Research in Multiple Sclerosis

WASHINGTON, June 01, 2007 /PRNewswire/ -- The annual meeting ofthe Consortium of Multiple Sclerosis Centers (CMSC), the largestmeeting devoted to the comprehensive care and science of multiplesclerosis (MS), is underway in the nation's capital today. Multiplesclerosis, a disease of the central nervous system that affects400,000 people in the United States, challenges patients, carepartne...

Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology

BERKELEY HEIGHTS, N.J., May 25, 2007 /PRNewswire-FirstCall/ --Genta Incorporated announced that several abstracts featuring itsoncology products, Genasense(R) (oblimersen sodium) Injection, andGanite(R) (gallium nitrate injection), will be presented at the43rd annual meeting of the American Society of Clinical Oncology(ASCO) in Chicago, June 1-5, 2007. The abstracts include thefollowing:...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data from arandomized, double-blind study showed that a combination ofCOPAXONE(R) (glatiramer acetate injection) along with the oralantibiotic minocycline reduced T1 Gadolinium (Gd)-enhancing lesionsof the brain by 63 percent (p=0.08) in patients with activerelapsing-remitting multiple sclerosis (RRMS), as measured bymagnetic resonance im...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

Treatment with Copaxone Plus Minocycline Showed SubstantialReduction of Disease Activity in Patients with ActiveRelapsing-Remitting Multiple Sclerosis Combination Treatment With Antibiotic Further Reduced BrainLesions and Was Well Tolerated KANSAS CITY, Mo, May 4, 2007 - New data from a randomized,double-blind study showed that a combination of Copaxone(glatiramer acetate in...

Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients

KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data havedemonstrated that relapsing-remitting multiple sclerosis (RRMS)patients treated with COPAXONE(R) (glatiramer acetate injection)following brief immunosuppression with mitoxantrone experienced a90 percent reduction in magnetic resonance imaging (MRI)-monitoreddisease activity compared to their baseline. These benefits wereachieved...

Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting

BOSTON--(BUSINESS WIRE)--May 2, 2007 - Acorda Therapeutics, Inc.(R)(Nasdaq: ACOR) today presented data from a Phase 3 clinical trialof Fampridine-SR in people with multiple sclerosis (MS) at theAmerican Academy of Neurology meeting. Andrew Goodman, M.D.,Director of the Multiple Sclerosis Center at the University ofRochester, presented top-line results on walking ability, legstrength, spasti...

Data Presented at the American Academy of Neurology's Annual Meeting Provide Update on Utilization and Safety of Tysabri in Patients with Multiple Sclerosis

BOSTON--(BUSINESS WIRE)--May 3, 2007 - Biogen Idec (NASDAQ: BIIB)and Elan Corporation, plc (NYSE: ELN) announced today that new datafrom the TOUCH Prescribing Program(TM) and TYGRIS safety studyconfirm the safety profile from previous clinical studies ofTYSABRI(R) (natalizumab). Also presented at the 59th annual meetingof the American Academy of Neurology in Boston, MA were extensionstudy d...

Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN

Interim analysis of Phase 2 comparative study showed significantresults in favor of alemtuzumab versus Rebif CAMBRIDGE, Mass. and WAYNE, N.J., May 02, 2007/PRNewswire-FirstCall/ -- Genzyme Corporation and Bayer HealthCarePharmaceutical today announced detailed interim results from theCAMMS223 Phase 2 study. This interim analysis of all patient datathrough at least twenty-four months from...

Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across Multiple Migraine Attacks

Study Results Show Individuals Reported Consistent Pain-FreeResults From Attack to Attack BOSTON, May 02, 2007 /PRNewswire/ -- Patients who suffer frommigraines frequently cite inconsistent effectiveness as a reasonfor their dissatisfaction with their medicine. New data from morethan 1,100 patients show that the investigational migraine therapyTrexima, when taken early, produced pain-free...

Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology

Rituxan Significantly Reduced Signs of Disease Activity as Measuredby MRI and Relapse -- Genentech, Inc.(NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced thatpositive data from a Phase II clinical study of Rituxan®(rituximab) in patients with relapsing-remitting multiple sclerosis(RRMS) were presented...

Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology

BOSTON--(BUSINESS WIRE)--May 1, 2007 - Genentech, Inc. (NYSE:DNA)and Biogen Idec, Inc. (Nasdaq:BIIB) announced that positive datafrom a Phase II clinical study of Rituxan(R) (rituximab) inpatients with relapsing-remitting multiple sclerosis (RRMS) werepresented today at the American Academy of Neurology annual meetingheld in Boston. Rituxan is a therapeutic antibody that targets andselectiv...

Laquinimod, a Novel Oral Compound, Showed Significant Reduction in Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)

JERUSALEM, & LUND, Sweden--(BUSINESS WIRE)--May 1, 2007 - TevaPharmaceutical Industries Ltd. and Active Biotech AB todayannounced that data from a 36-week, randomized, double-blind,placebo-controlled Phase IIb study demonstrated that an oral 0.6 mgdose of laquinimod given daily significantly reduced magneticresonance imaging (MRI) disease activity by 38 percent in RRMSpatients and was w...

Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)

JERUSALEM--(BUSINESS WIRE)--Apr 17, 2007 - A 9-month, randomized,double-blind, parallel-group Phase II study of 90 patientscomparing a 40 mg dose of COPAXONE(R) given daily to the currentlyapproved COPAXONE(R) 20 mg dose showed a 38 percent greaterreduction in inflammatory disease activity as measured by magneticresonance images (MRI) of the brain. In addition, patients takingCOPAXONE(R) 40...

Threshold Pharmaceuticals Announces Multiple Presentations on Oncology Pipeline at the 2007 American Association for Cancer Research (AACR) Annual Meeting

REDWOOD CITY, Calif., April 16, 2007 /PRNewswire-FirstCall/ --Threshold Pharmaceuticals, Inc. , today announced multiplepresentations regarding its oncology pipeline, which includes twopreclinical presentations on the Hypoxically Activated Prodrug,TH-302, and two research presentations from Threshold's TubulinInhibitor program. The presentations will take place at the 2007American Associ...

Sunesis Presents Data Supporting SNS-032's Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting

Results from Non-clinical Studies Confirm Mechanism of Action andProvide Guidance for Dosing SOUTH SAN FRANCISCO, April 16, 2007 /PRNewswire-FirstCall/ --Sunesis Pharmaceuticals, Inc. presented non-clinical datademonstrating SNS-032's apoptotic activity in a multiple myelomamodel. These data were presented today in a poster session duringthe Annual Meeting of the American Association for...

New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 13, 2007 - Biogen Idec Inc.(NASDAQ: BIIB) announced today that one-year data presented at theAcademy of Managed Care Pharmacy's (AMCP) 2007 Annual Meeting showthat AVONEX(R) (Interferon beta-1a) is a cost-effective therapy inmultiple sclerosis (MS) when compared to other interferon betatreatments. Using a comprehensive analysis of medical and pharmacyc...

Ascenta Therapeutics Highlights Multiple Data Presentations at Upcoming AACR Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Apr 13, 2007 - Ascenta Therapeutics,Inc. announced today that its small molecule portfolio ofapoptosis-triggering compounds will be featured in three oralpresentations and several poster presentations at next week's 2007Annual Meeting of the American Association for Cancer Research(AACR), to be held in Los Angeles, California April 14-18, 2007. Ascenta's MDM2 p...

ANA380 Exhibits Activity In Vitro Against Multiple Clinically Relevant Hepatitis B Virus Mutants

Poster Presentation at EASL on April 13, 2007, 2007 SAN DIEGO, and SEOUL, South Korea, April 13/PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. and LG LifeSciences, Ltd., presented data from an in vitro study showing thatANA380 (LB80380) retains potency against multiple mutant strains ofhepatitis B virus (HBV) which are resistant to lamivudine,adefovir, entecavir or telbivudine, dur...

Gloucester Pharmaceuticals Announces Multiple Presentations of Preclinical Romidepsin Data at American Association of Cancer Research Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 11, 2007 - GloucesterPharmaceuticals, Inc., an oncology focused biopharmaceuticalcompany, announced today that several abstracts coveringpreclinical work with romidepsin will be presented at the 2007Annual Meeting of the American Association of Cancer Researchtaking place in Los Angeles, CA April 14-18, 2007. Thesepresentations will focus on a variety...

First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

KANSAS CITY, Mo.--(BUSINESS WIRE)--Apr 11, 2007 - A comparison ofthe long-term economic outcomes of four immunomodulatory drugtherapies combined with symptom management versus symptommanagement alone revealed that COPAXONE(R) (glatiramer acetateinjection) was the most cost-effective treatment strategy forrelapsing-remitting multiple sclerosis (RRMS). The study providesthe first pharmacoecon...

Low-Dose Steroid Combined With Lenalidomide Prolongs Survival Compared With High-Dose Steroid for Multiple Myeloma Treatment

WASHINGTON, April 4, 2007-Preliminary results from a large,randomized clinical trial for patients with newly diagnosedmultiple myeloma, a cancer typically found in bone marrow, hasshown that the use of a low dose of the steroid dexamethasone(Decadron ®), in combination with lenalidomide (Revlimid ®)is associated with improved survival when compared to a treatmentregimen with lenalid...

SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at AACR

DUBLIN, Calif., April 04, 2007 /PRNewswire-FirstCall/ --SuperGen Inc. announced today that it will have multiplepresentations at the American Association for Cancer ResearchAnnual Meeting on April 14-18 in Los Angeles. These presentationswill focus on data concerning many of SuperGen's current oncologyprograms including its lead tyrosine kinase inhibitor compound,MP470 and its ability to...

ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma

SUMMIT, N.J., April 04, 2007 /PRNewswire-FirstCall/ -- CelgeneCorporation announced that the Eastern Cooperative Oncology Group(ECOG) has reported that its Data Monitoring Committee's (DMC)review of preliminary results from a large, randomized clinicaltrial for patients with newly diagnosed multiple myeloma has foundthat the use of a low dose of dexamethasone (Decadron) incombination wit...

Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis

THE WOODLANDS, Texas--(BUSINESS WIRE)--Apr 3, 2007 - OpexaTherapeutics, Inc. (NASDAQ: OPXA), a company involved in thedevelopment and commercialization of cell therapies, todayannounced positive top-line data in an open-label Phase I/II doseescalation clinical trial of the investigational T-cell vaccine,Tovaxin(TM), for multiple sclerosis. In this one-year, 10-subjectdose escalation clinica...